drugset / Trial / NCT02508805

Safety and Efficacy of Neuromultivit in Treatment of Vertebrogenic Radiculopathy

NCT02508805

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to assess the efficacy and safety of Neuromultivit (solution for injections) in treatment of vertebrogenic radiculopathy L5, S1 in comparison with standard therapy. The patients are randomised into two groups: standard therapy group and standard therapy plus Neuromultivit group.

Timeline

Start
2015-05
Primary completion
2015-09
Completion
2015-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Neuromultivit Unknown 2 ml Intramuscular
Background Diclofenac Other / unclassified 100 mg Oral
Background Tizanidine Small molecule 2 mg Oral

Indications